Pharmac is funding new medicine for people with attention deficit hyperactivity disorder (ADHD) and narcolepsy, and removing ...

Pharmac is funding Lisdexamfetamine for ADHD and narcolepsy, benefiting more than 6000 people from December. Pharmac is ...

Get detailed information on Lisdexamfetamine, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated ...

Pharmac has announced it'll fund new stimulant medicine lisdexamfetamine from December. The medicine -- branded as Vyvanse -- is taken once a day. Chief medical officer, David Hughes, says it's a ...

From 1 December 2024, Pharmac is also removing the renewal criteria for methylphenidate, dexamfetamine and modafinil, medicines used to treat ADHD and narcolepsy. This means that once an initial ...

Viatris Inc. VTRS delivered third-quarter 2024 adjusted earnings of 75 cents per share, which beat the Zacks Consensus ...

Viatris reports Q3 2024 net sales of $3.74 billion, beating estimates. Adjusted EPS at $0.75 surpasses $0.68 consensus. 2024 ...

Q3 2024 Earnings Call Transcript November 7, 2024 Operator: Good morning, everyone, and welcome to the Viatris Q3 2024 Earnings Call. All participants will be in a listen-only mode. [Operator ...

Drugmaker Viatris beat Wall Street estimates for third-quarter profit and revenue on Thursday, helped by strong demand for its new generic asthma and ADHD drugs, among others, sending its shares up 2.

Adults with attention-deficit/hyperactivity disorder (ADHD) are more frequently presenting for diagnosis and treatment. Medication is considered to be appropriate ...

First-line medications for the treatment of ADHD are stimulants (methylphenidate, mixed amphetamine salts, and amphetamine derivatives - lisdexamfetamine and dextroamphetamine). Second-line ...